Can-Fite BioPharma (CANF) –
-
Form 6-K Can-Fite BioPharma Ltd. For: Apr 15
-
Can-Fite Bio (CANF) Announces Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
-
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
-
Form EFFECT Can-Fite BioPharma Ltd.
-
Form S-8 Can-Fite BioPharma Ltd.
-
Form POS AM Can-Fite BioPharma Ltd.
-
Form 6-K Can-Fite BioPharma Ltd. For: Apr 03
-
Can-Fite BioPharma (CANF) Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
-
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
-
Form 20-F Can-Fite BioPharma Ltd. For: Dec 31
-
Form 6-K Can-Fite BioPharma Ltd. For: Mar 28
-
Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
-
Can-Fite Reports 2023 Financial Results and Clinical Update
-
Form 6-K Can-Fite BioPharma Ltd. For: Mar 11
-
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
-
Form 6-K Can-Fite BioPharma Ltd. For: Feb 28
-
Can-Fite BioPharma (CANF) Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
-
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
-
Form SC 13G Can-Fite BioPharma Ltd. Filed by: ARMISTICE CAPITAL, LLC
-
Form 6-K Can-Fite BioPharma Ltd. For: Jan 30
-
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
-
Form 6-K Can-Fite BioPharma Ltd. For: Jan 29
-
Can-Fite BioPharma (CANF) Reports Publication Showing Positive Data from COMFORT-1 Phase III Psoriasis Study
-
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
-
Form EFFECT Can-Fite BioPharma Ltd.
-
Form F-3/A Can-Fite BioPharma Ltd.
-
Form 6-K Can-Fite BioPharma Ltd. For: Dec 20
-
Can-Fite BioPharma (CANF) Reports New Data on Namodenoson’s Anti-obesity Mechanism of Action
-
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
-
Form 6-K Can-Fite BioPharma Ltd. For: Dec 18
-
Can-Fite BioPharma (CANF) Received FDA Positive Response to Psoriasis Pediatric Plan
-
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
-
Form F-3 Can-Fite BioPharma Ltd.
-
Form 6-K Can-Fite BioPharma Ltd. For: Dec 04
-
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
-
Form 6-K Can-Fite BioPharma Ltd. For: Nov 30
-
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
-
Form 424B3 Can-Fite BioPharma Ltd.
-
Form 6-K Can-Fite BioPharma Ltd. For: Nov 22
-
Form 6-K Can-Fite BioPharma Ltd. For: Nov 21
-
Can-Fite BioPharma (CANF) Announces Exercise of Warrants for Approximately $3M in Gross Proceeds
-
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
-
Form 6-K Can-Fite BioPharma Ltd. For: Nov 21
-
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
-
Form 6-K Can-Fite BioPharma Ltd. For: Nov 01
-
Can-Fite BioPharma (CANF) Issues Business Update
-
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
-
Form 6-K Can-Fite BioPharma Ltd. For: Oct 30
-
Can-Fite BioPharma (CANF) Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal
-
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
Back to CANF Stock Lookup
